سعر سالميتوكورت 100/50مكجم 60 كبسولة استنشاق + جهاز استنشاق 2024

Salmetocort 100/50 mcg is an Egyptian (Eva Pharma) inhalation-powder product supplied as 60 capsules with an inhaler device; each capsule contains fluticasone 100 mcg and salmeterol 50 mcg (inhaled corticosteroid plus long-acting beta2 agonist) for regular maintenance treatment of asthma and, at suitable strengths, COPD.

• Regular treatment of asthma where a combination of a long-acting beta2 agonist and an inhaled corticosteroid is appropriate (not controlled on inhaled corticosteroid plus as-needed short-acting beta2 agonist, or already controlled on both)Population: Adults, adolescents and children 4 years and olderelectronic medicines compendium (emc), UK

• Very common: headache, nasopharyngitis. Common: candidiasis of the mouth and throat, pneumonia and bronchitis (in COPD), hypokalaemia, throat irritation, hoarseness/dysphonia, sinusitis, contusions, muscle cramps, traumatic fractures, arthralgia, myalgia. Uncommon/rare: tremor, palpitations, tachycardia, arrhythmias, hyperglycaemia, anxiety, sleep disorders, cataract, hypersensitivity reactions, paradoxical bronchospasm, systemic corticosteroid effects.International label, equivalent formulation · electronic medicines compendium (emc), UK

• Hypersensitivity to the active substances or to any excipient.International label, equivalent formulation · electronic medicines compendium (emc), UK
• Primary treatment of status asthmaticus or other acute episodes of asthma or COPD requiring intensive measures; severe hypersensitivity to milk proteins (lactose-containing powder).International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)

• Not for acute symptoms; do not initiate during an exacerbation or rapidly deteriorating asthma. Serious asthma-related adverse events may occur; increasing reliever use signals loss of control and needs medical review.International label, equivalent formulation · electronic medicines compendium (emc), UK
• Use with caution in severe cardiovascular disease, arrhythmias, diabetes mellitus, thyrotoxicosis or uncorrected hypokalaemia; paradoxical bronchospasm may occur (stop immediately and use a rapid-acting bronchodilator).International label, equivalent formulation · electronic medicines compendium (emc), UK
• Systemic corticosteroid effects (adrenal suppression, Cushingoid features, reduced bone density, growth retardation in children, cataract, glaucoma) may occur, particularly with high doses for long periods; use the lowest effective dose; caution in pulmonary tuberculosis and airway infections.International label, equivalent formulation · electronic medicines compendium (emc), UK

• Ritonavir, cobicistat, ketoconazole, itraconazole and other strong CYP3A4 inhibitorsMarkedly increase systemic fluticasone (Cushing syndrome, adrenal suppression) and salmeterol exposure (QTc prolongation, palpitations); avoid unless benefit outweighs risk.electronic medicines compendium (emc), UK
• Beta-adrenergic blockersMay weaken or antagonise the effect of salmeterol; both selective and non-selective beta blockers should be avoided unless there are compelling reasons.electronic medicines compendium (emc), UK
• Xanthine derivatives, steroids and diureticsMay potentiate beta2-agonist-induced hypokalaemia, especially in acute severe asthma.electronic medicines compendium (emc), UK

• A large amount of data (more than 1000 pregnancy outcomes) indicates no malformative or feto/neonatal toxicity; use only if the expected benefit to the mother outweighs any possible risk to the fetus, using the lowest effective fluticasone dose.International label, equivalent formulation · electronic medicines compendium (emc), UK
• Unknown whether salmeterol or fluticasone propionate pass into human milk (both are excreted in rat milk); a risk to the breastfed infant cannot be excluded; weigh benefit of breastfeeding against benefit of therapy.International label, equivalent formulation · electronic medicines compendium (emc), UK

English text not available for this section.